Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07044336) titled 'Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)' on June 23.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor).
Primary Sponsor: AstraZeneca
Condition:
Endometrial Cancer
Malignant Solid Tumour
Intervention:
Drug: Puxitatug Samrotecan
Drug: Doxorubicin
Recruitment Status: Recruiting
Phase: Phase 3
Date of First Enrollment: August 1, 2025
Target Sample Size: 700
Countries of Recruitment:
United States
Argentina
Au...